Track Shield Therapeutics plc — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Shield Therapeutics plc STX.L · Stock Open Shield Therapeutics plc in new tab

3.20 GBX
EPS
-0.01
P/B
-2.62
Beta
1.73
Target Price
15.67 GBX
Loading chart...
Key Metrics
Earnings dateApril 29, 2027
EPS-0.01
Book Value-0.01
Price to Book-2.62
% Insiders61.505%
Growth
Revenue Growth0.42%
Estimates
Forward P/E5.70
Forward EPS0.01
Target Mean Price15.67

DCF valuation

Model fair value for Shield Therapeutics plc (STX.L)
Result
Sign in to run the valuation for STX.L.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
3 analysts · consensus Strong buy · mean target 15.67 GBX (low 9.00, high 23.00) · as of 9 Nov 2026
Low 9.00
Mean 15.67
High 23.00
Price 3.20
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Shield Therapeutics plc Logo Shield Therapeutics plc Analysis (STX.L)

United Kingdom Health Care Official Website Stock

Is Shield Therapeutics plc a good investment? Shield Therapeutics plc (STX.L) is currently trading at 3.20 GBX. Market analysts have a consensus price target of 15.67 GBX. This suggests a potential upside from current levels.

Earnings Schedule: Shield Therapeutics plc is expected to release its next earnings report on April 29, 2027. The market consensus estimate for Forward EPS is 0.01.

Investor FAQ

Does Shield Therapeutics plc pay a dividend?

No, it does not currently pay a dividend.

What asset class is Shield Therapeutics plc?

Shield Therapeutics plc is classified as a Stock. You can compare it against 3 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be April 29, 2027. The company currently has a trailing EPS of -0.01.

Company Profile

Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on development and commercialization of clinical-stage pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru (ferric maltol), a non-salt based oral therapy for patients to treat the iron deficiency with or without anemia. Shield Therapeutics plc was incorporated in 2008 and is based in Gateshead, United Kingdom.

Exchange Ticker
FRA (Germany) 1JS.F
LSE (United Kingdom) STX.L
PNK (United States) SHIEF
Trades
Dividend History paid per year (GBX)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
March 1, 2021 1.029
Dec. 16, 2022 1.029
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion